论文部分内容阅读
Cyr61 is a potential prognostic marker for prostate cancer
【机 构】
：
Department of Urology, the James Buchanan Brady Urological Institute, The Johns Hopkins University S
【出 处】
：
亚洲男性学杂志（英文版）
【发表日期】
：
2012年3期
其他文献
Prostate intervention versus observation trial (PIVOT) is the largest and longest randomized trial conducted in men with early stage prostate cancer detected during the era of wide-spread prostate-specific antigen (PSA) testing.1 PIVOT enrolled 731 men an
期刊
Dear Editor,rnWe present here a rare case of primary malignant lymphoma of the glans penis that was detected in a 72-year-old man.Additionally,we have reviewed the literature for reports of primary malignant lymphoma of the penis.This is most likely the f
期刊
External validation of the Prostate Cancer Prevention Trial and the European Randomized Study of Scr
The aging process is the major risk factor for disease and disability yet the cellular mechanisms for aging are uncertain.By studying transgenic mice with altered expression of the DNA repair enzyme,ERCC1,it was concluded that DNA damage is an important,i
期刊
Hypoxia has been identified as a common environmental stress factor associated with therapeutic resistance and metastasis in human cancers.A major player in regulating the response to hypoxia is the transcriptional factor hypoxia-inducible factor 1 alpha
期刊